Clinical Trial Update: Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 study evaluating RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant for locally advanced or metastatic PIK3CA-mutant HR+/HER2- breast cancer; currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hr-positive Breast Cancer

Drugs mentioned

• Capivasertib (capivasertib)
• Fulvestrant (fulvestrant)
• RLY-2608

Snippet

Sponsor: Relay Therapeutics, Inc. | Conditions: PIK3CA Mutation, HER2- Negative Breast Cancer | Phase 3 | Status: RECRUITING